|Targets||Orexin Receptor (OX Receptor)|
|Description||MK3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. MK-3697 is also the third insomnia product, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species.|
|Appearance||white solid powder|
|Synonyms||MK-3697; MK3697; MK 3697.|
ACT 335827 has been found to be an orexin OX1 receptor antagonist and could probably exhibit anxiolytic effects in vivo.
SB-408124 (Hydrochloride) is the hydrochloride salt form of SB-408124. SB-408124 is a selective antagonist of OX1 (for human OX1 Kb= 21.7nM; for human OX2 Kb=14...
SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity ove...
SB-649868 is a novel, orally active dual orexin receptor antagonist of orexin(OX)1 and OX2 receptor (pKi=9.4 and 9.5 at the OX1 and OX2 receptor, respectively),...
SB-334867 free base is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.
Almorexant HCl is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, re...
Filorexant, a selective reversible and orally bioavaliable antagonist of OX(1)R receptor and OX(2)R receptor, could probably be an effective compound in the tre...
[Ala11,D-Leu15]-Orexin B is a selective OX2 receptor agonist with EC50 values are 0.13nM for human OX2.